Status:
COMPLETED
Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)
Lead Sponsor:
Boehringer Ingelheim
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Heart Failure
Eligibility:
All Genders
Brief Summary
Study objective is to investigate the safety and effectiveness of long-term daily use of JARDIANCE® Tablets in patients with chronic heart failure (CHF) under real-world use.
Eligibility Criteria
Inclusion
- Patients with chronic heart failure (CHF) failure who are prescribed with JARDIANCE® Tablets in Japan
- Patients who have never been treated with Empagliflozin (including treatment for type 2 diabetes mellitus (T2DM)) before enrolment
Exclusion
- None
Key Trial Info
Start Date :
April 15 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 28 2024
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT05262764
Start Date
April 15 2022
End Date
June 28 2024
Last Update
August 6 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nippon Boehringer Ingelheim Co., Ltd.
Tokyo, Japan, 1416017